< Back to previous page
Researcher
Eric Van Cutsem
- Disciplines:Oncology
Affiliations
- Digestive Oncology (Division)
Member
From1 Aug 2022 → Today - Clinical Digestive Oncology (Division)
Member
From1 Jan 2012 → 31 Jul 2022 - Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → 31 Dec 2011
Projects
1 - 10 of 13
- SAFIR-ABC10: molecular screening for precision medicine in advanced biliary cancersFrom1 Jan 2022 → TodayFunding: Foundations, funds and other with scientific goal
- The search for biomarkers in systemic treatment of advanced hepatocellular carcinoma.From1 Oct 2019 → 1 Oct 2023Funding: FWO Strategic Basic Research Grant
- Transient Receptor Potential (TRP) channels in Chemotherapy-Induced Peripheral Neuropathy (CIPN): Translational research from bench to bedsideFrom10 Sep 2018 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Identification of candidate biomarkers of intrinsic and acquired resistance to anti-angiogenic agents in metastatic colorectal cancer.From1 Jan 2013 → 31 Dec 2014Funding: Private funding of national origin - undefined
- Genetic biomarkers for anti-angiogenic therapies - a translational approach.From1 Jan 2011 → 31 Dec 2013Funding: Private funding of national origin - undefined
- The role of the forkhead transcription factor FOXP1 in cancer.From1 Jan 2011 → 31 Dec 2014Funding: FWO research project (including WEAVE projects)
- Technical research platform & heavy equipment HiSeq200 (including CBOT computing system and warranty).From1 Sep 2010 → 31 Aug 2013Funding: Other federal scientific institutions
- Can response to Epidermal Growth Factor Receptor antibodies in patients with metastatic Colorectal Cancer be predicted? Advanced bio-informatics tools, integrating gene mutation, microarray and proteomics data may hold the key.From1 Jan 2009 → 31 Dec 2012Funding: FWO research project
- Imaging for early response prediction to EGF-receptor blocking monoclonal antibodies in combination therapy for colorectal cancer.From1 Jan 2009 → 31 Dec 2012Funding: IWT - TBM (Applied Biomedical Research)
- Can response to epidermal growth factor receptor antibodies in metastatic colorectal cancer be predicted? Advanced bio-informatics tools integrating gene mutation and microarray data may hold the key.From1 Jan 2009 → 31 Dec 2012Funding: Private funding of national origin - undefined
Publications
41 - 50 of 727
- Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer(2022)
Authors: Baki Topal, Eric Van Cutsem
- First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study(2022)
Authors: Eric Van Cutsem
Pages: 161 - + - Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial(2022)
Authors: Eric Van Cutsem
Pages: 197 - 206 - The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer(2021)
Authors: Eric Van Cutsem
Pages: 727 - + - Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival(2021)
Authors: Eric Van Cutsem
- Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database(2021)
Authors: Eric Van Cutsem
Pages: 1693 - 1704 - Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study(2021)
Authors: Eric Van Cutsem
- Lu-177-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial(2021)
Authors: Eric Van Cutsem
Pages: 1752 - 1763 - Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061(2021)
Authors: Eric Van Cutsem
Pages: 1330 - 1340 - Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study(2021)
Authors: Eric Van Cutsem
Pages: 1769 - 1778